Macrophage-tumor cell fusions from peripheral blood of melanoma patients

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Clawson, Gary A ^a   Matters, Gail L ^a   Xin, Ping ^a   Imamura Kawasawa, Yuka ^a   Du, Zhen ^a   Thiboutot, Diane M ^a   Helm, Klaus F ^a   Neves, Rogerio I ^a   Abraham, Thomas ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; B RAF KINASE; CD14 ANTIGEN; CD163 ANTIGEN; CD204 ANTIGEN; CD206 ANTIGEN; CD68 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; EPITHELIAL CELL ADHESION MOLECULE; EXTRACHROMOSOMAL DNA; HERMES ANTIGEN; KERATIN; LYMPHOCYTE ANTIGEN; MACROPHAGE MIGRATION INHIBITION FACTOR; MELAN A; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; CELL ADHESION MOLECULE; CHROMATIN; EPCAM PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER; TUMOR PROTEIN;

ANEUPLOIDY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; AUTOPHAGY; BLOOD SAMPLING; CANCER CELL; CANCER CELL CULTURE; CELL FUSION; CELL ISOLATION; CELL MOTILITY; CELL POPULATION; CELL SIZE; CELL STRUCTURE; CELL ULTRASTRUCTURE; CELL VACUOLE; CHROMATIN STRUCTURE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CUTANEOUS MELANOMA; CYTOKINE RELEASE; DISTANT METASTASIS; DNA CONTENT; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VIVO STUDY; LAMELLIPODIUM; LYSOSOME; MACROPHAGE; MELANOSOME; METASTASIS POTENTIAL; MICRONUCLEUS; MITOCHONDRION; MOUSE; NONHUMAN; NUDE MOUSE; PLOIDY; PSEUDOPODIUM; STEM CELL; TUMOR XENOGRAFT; ANIMAL; CANCER STEM CELL; CHROMATIN; DRUG SCREENING; EPITHELIAL MESENCHYMAL TRANSITION; GENETICS; MELANOCYTE; MELANOMA; METABOLISM; PATHOLOGY; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; CELL ADHESION MOLECULES; CELL FUSION; CHROMATIN; EPITHELIAL CELL ADHESION MOLECULE; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MACROPHAGES; MELANOCYTES; MELANOMA; MICE; MICROSCOPY, CONFOCAL; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; PROTO-ONCOGENE PROTEINS B-RAF; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942848393     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134320     Document Type: Article

References (107)

1. Chaffer CL, Weinberg D. A perspective on cancer cell metastasis. Science. 2011; 331:1559-64. doi:10.1126/science.1203543 PMID: 21436443
2. Zhang L, Ridgway LD, Wetzel MD, Ngo J, Yin W, Kumar D, et al. The identifcation and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med. 2013; 5(180):ra48.
3. Markiewicz A, Ksiazkiewicz M, Seroczynska B, Skokowski J, Szade J, Welnicka-Jaskiewicz M, et al. Heterogeneity of mesenchymal markers expression-molecular profiles of cancer cells disseminated by lymphatic and hematogenous routes in breast cancer. Cancers (Basel). 2013; 5(4):1485-503.
4. Li YM, Xu SC, Li J, Han KQ, Pi HF, Zheng L, et al. Epithelial-mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease. Cell Death Dis. 2013; 4:e831. doi:10.1038/cddis.2013.347 PMID: 24091674
5. Friedlander TW, Ngo VT, Dong H, Premasekharan G, Weinberg V, Doty S, et al. Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer. Int J Cancer. 2014; 134(10):2284-93. doi:10.1002/ijc.28561 PMID: 24166007
6. Friedlander TW, Premasekharan G, Paris PL. Looking back, to the future of circulating tumor cells. Pharmacol Ther. 2013;S0163-7258.
7. Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastsis in a xenograft assay. Nat Biotech. 2013; 31:539-44.
8. Grover PK, Cummins AG, Price TJ, Roberts-Thomson IC, Hardingham JE. Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research. Ann Oncol. 2014;March 20 Epub.
9. Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):824-6.
10. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26:3213-21. doi:10.1200/JCO.2007.15.8923 PMID: 18591556
11. Ma X, Xiao Z, Li X, Wang F, Zhang J, Zhou R, et al. Prognostic role of circulating tumor cells and disseminated tumor cells in patients with prostate cancer: a systematic review and meta-analysis. Tumour Biol. 2014;Feb22 Epub.
12. Karamitopoulou E, Zilobec I, Born D, Kondi-Pafiti A, Lykoudis P, Mellou A, et al. Tumor budding is a strong and independent prognostic factor in pancreatic cancer. Eur J Cancer. 2013; 49:1032-9. doi:10.1016/j.ejca.2012.10.022 PMID: 23177090
13. Karamitopoulou E. Tumor budding cells, cancer stem cells and epithelial-mesenchymal transitiontype cells in pancreatic cancer. Front Oncology. 2013; 2:209.
14. Baccelli I, Trumpp A. The evolving concept of cancer and metastasis stem cells. J Cell Biol. 2012; 198:281-93. doi:10.1083/jcb.201202014 PMID: 22869594
15. Clawson GA. Cancer. Fusion for moving. Science. 2013; 342(6159):699-700. doi:10.1126/science.1244270 PMID: 24202164
16. Hood JL, San Roman S, Wickline SA. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res. 2011; 71:3792-801. doi:10.1158/0008-5472.CAN-10-4455 PMID: 21478294
17. Pawelek JM, Chakraborty AK. The cancer cell-leukocyte fusion theory of metastasis. Adv Cancer Res. 2008; 101:397-444. doi:10.1016/S0065-230X(08)00410-7 PMID: 19055949
18. Lazova R, LeBerge GS, Duvall E, Spoelstra N, Klump V, Sznol M, et al. A melanoma brain metastasis with a donor-patient hybrid genome following bone marrow transplantation: first evidence for fusion in human cancer. PLoS One. 2013; 8(6):e66731. PMID: 23840523
19. Powell AE, Anderson EC, Davies PS, Silk AD, Pelz C, Impey S, et al. Fusion between intestinal epithelial cells and macrophages in a cancer context results in nuclear reprogramming. Cancer Res. 2011; 71:1497-505. doi:10.1158/0008-5472.CAN-10-3223 PMID: 21303980
20. Ambrosi DJ, Tanasijevic B, Kaur A, Obergfell C, O'Neill RJ, KruegerW, et al. Genome-wide reprogramming in hybrids of somatic cels and embryonic stem cells. Stem Cells. 2007; 25(5):1104-13. PMID: 17272499
21. Tsubouchi T, Soza-Ried J, Brown K, Piccolo FM, Cantone I, Landeira D, et al. DNA synthesis is required for reprogramming mediated by stem cell fusion. Cell. 2013; 152:873-83. doi:10.1016/j.cell.2013.01.012 PMID: 23415233
22. Brown KE, Bagci H, Soza-Ried J, Fisher AG. Atypical heterochromatin organization and replication are rapidly acquired by somatic cells following fusion-mediated reprogramming by mouse ESCs. Cell Cycle. 2013; 12:3253-61. doi:10.4161/cc.26223 PMID: 24036550
23. Schramm HM. Should EMT of cancer cells be understood as epithelial-myeloid transition. J Cancer. 2014; 5(2):125-32. doi:10.7150/jca.8242 PMID: 24494030
24. Ding J, Jin W, Chen C, Shao Z, Wu J. Tumor associated macrphage X cancer cell hybrids may acquire cancer stem cell properties in breast cancer. PLoS One. 2012; 7:e41942. doi:10.1371/journal.pone.0041942 PMID: 22848668
25. Sieweke MH, Allen JE. Beyond stem cells: Self-renewal of differentiated macrophages. Science. 2013; 342:1242974. doi:10.1126/science.1242974 PMID: 24264994
26. Clawson GA, Kimchi E, Patrick SD, Xin P, Harouaka R, Zheng S, et al. Circulating tumor cells in melanoma patients. PLoS One. 2012; 7(7):e41052. doi:10.1371/journal.pone.0041052 PMID: 22829910
27. Comai L. The advantages and disadvantages of being polyploid. Nat Rev Genet. 2005; 6:836-46. PMID: 16304599
28. Ploeger LS, Dullens H, Huisman PJ, van Diest PJ. Fluorescent stains for quantification of DNA by confocal laser scanning microscopy in 3-D. Biotech Histochem. 2008; 83(2):1-7.
29. Huisman A, Ploeger LS, Dullens H, Jonges TN, Belien JA, Meijer GA, et al. Discrimination between benign and malignant prostate tissue using chromatin texture analysis in 3-D by confocal laser scanning microscopy. The Prostate. 2006; 67:248-54.
30. Ohlund D, Franklin O, Lundberg E, Lundin C, Sund M. Type IV collagen stimulates pancreatic cancer cell proliferation, migration, andinhibits apoptosis through an autocrine loop. BMC Cancer. 2013; 13:154. doi:10.1186/1471-2407-13-154 PMID: 23530721
31. Lo MC, Yip TC, Ngan KC, Cheng WW, Law CK, Chan PS, et al. Role of MIF/CXCL8/CXCR2 signaling in the growth of nasopharyngeal carcinoma tumor spheres. Cancer Lett. 2013;Epub Feb 8.
32. Bernhagen J, Krohn R, KLue H, Gregory JL, Zernecke A, Koenen RR, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med. 2007; 13:587-96. PMID: 17435771
33. Shi X, Leng L, Wang T, Wang W, Du X, Li J, et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity. 2006; 25:595-606. PMID: 17045821
34. Maul GG, Romsdahl MM. Ultrastructural comparison of two human malignant melanoma cell lines. Cancer Res. 1970; 30:2782-90. PMID: 5487065
35. Grimaldi AM, Cassidy PB, Leachmann S, Ascierto PA. Novel approaches in melanoma prevention and therapy. Cancer Treat Res. 2014; 159:443-55. doi:10.1007/978-3-642-38007-5-25 PMID: 24114495
36. Tekola P, Baak JP, Van Ginkel HA, Belien JA, Van Diest PJ, Broeckaert MA, et al. Three-dimensional confocal laser scanning DNA ploidy cytometry in thick histological sections. J Pathol. 1996; 180:214-22. PMID: 8976883
37. Lazebnik Y. The shock of being united and symphiliosis. Another lesson from plants? Cell Cycle. 2014; 13: 2323-29. doi:10.4161/cc.29704 PMID: 25483182
38. Kumeta M, Hirai Y, Yoshimura SH, Horigome T, Takeyasu K. Antibody-based analysis reveals "filamentous vs. non-filamentous" and "cytoplasmic vs. nuclear" crosstalk of cytoskeletal proteins. Exp Cell Res. 2013; 319(19):3226-37.
39. Drabeni M, Lopez-Vilaro L, Barranco C, Trevisan G, Gallardo F, Pujol RM. Differences in tumor thickness between hematoxylin and eosin and Melan-A immunohistochemically stained primary cutaneous melanomas. Am J Dermatopathol. 2013; 35(1):56-63. doi:10.1097/DAD.0b013e31825ba933 PMID: 22688397
40. Jannie KM, Stipp CS, Weiner JA. ALCAM regulates motility, invasiveness, and adherens junction formation in uveal melanoma cells. PLoS One. 2012; 7(6):e39330. doi:10.1371/journal.pone.0039330 PMID: 22745734
41. Weidle U, Eggle D, Klostermann S, Swart GW. ALCAM/CD166: cancer-related issues. Cancer Genomics Prteomics. 2010; 7(5):231-43.
42. Kanno H, Nishihara H, Wang L, Yuzawa S, Kobayashi H, Tsuda M, et al. Expression of CD163 prevents apoptosis through the production of granulocyte colony-stimulating factor in meningioma. Neuro Oncol. 2013; 17(7):853-64.
43. Lan C, Huang X, Lin S, Huang H, Cal Q, Wan T, et al. Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer. Technol Cancer Res Treat. 2013; 12(3):259-67. doi:10.7785/tcrt.2012.500312 PMID: 23289476
44. Matsumura Y, Ishii G, Aokage K, Kuwata T, Hishida T, Yoshida J, et al. Morphophenotypic characteristics of intralymphatic cancer and stromal cells susceptible to lymphogenic metastasis. Cancer Sci. 2012; 103(7):1342-7. doi:10.1111/j.1349-7006.2012.02275.x PMID: 22429811
45. Salmi M, Karikoski M, Elima K, Rantakari P, Jalkanen S. CD44 binds to macrophage mannose receptor on lymphatic endothelium and supports lymphocyte migration via afferent lymphatics. Circ Res. 2013; 112(12):1577-82. doi:10.1161/CIRCRESAHA.111.300476 PMID: 23603511
46. Swierczynski J, Hebanowska A, Sledzinski T. Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer. World J Gastroenterol. 2014; 20(9):2279-303. doi:10.3748/wjg.v20.i9.2279 PMID: 24605027
47. Baenke F, Peck B, Miess H, Schulze A. Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. Dis Model Mech. 2013; 6(6):1353-63. doi:10.1242/dmm.011338 PMID: 24203995
48. Seguin F, Carvalho MA, Bastos DC, Agostini M, Zecchin KG, Alvarez-Flores MP, et al. The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-10 melanomas. Br J Cancer. 2012; 107(6):077-87.
49. Zecchin KG, Rossato FA, Raposo HF, Melo DR, Alberici LC, Oliveira HC, et al. Inhibition of fatty acid synthase in melanoma cells activates the intrinsic pathway of apoptosis. Lab Invest. 2011; 91(2):232-40. doi:10.1038/labinvest.2010.157 PMID: 20805790
50. de Andrade BA, Leon JE, Carlos R, Delgado-Azanero W, Mosqueda-Taylor A, Graner E, et al. Expression of fatty acid synthase (FASN) in oral nevi and melanoma. Oral Dis. 2011; 17(8):808-12. doi:10.1111/j.1601-0825.2011.01841.x PMID: 21819495
51. Pandev V, Vijayakumar MV, Ajay AK, Malvi P, Bhat MK. Diet-induced obesity increases melanoma progression: involvement of Cav-1 and FASN. Int J Cancer. 2012; 130(2):497-508.
52. Haq R, Fisher dE, Widlund HR. Molecular Pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation. Clin Cancer Res. 2014; 20(9):2257-63. doi:10.1158/1078-0432.CCR-13-0898 PMID: 24610826
53. Itakura E, Huang RR, Wen DR, Cochran AJ. "Stealth" melanoma cells in histology-negative sentinel lymph nodes. Am J Surg Pathol. 2011; 35(11):1657-65. doi:10.1097/PAS.0b013e3182322cf7 PMID: 21997686
54. Madsen DH, Leonard D, Masedunskas A, Moyer A, Jurgensen HJ, Peters DE, et al. M2-like macrophages are responsible for collagen degradation through a mannose receptor-mediated pathway. J Cell Biol. 2013; 202:951-66. doi:10.1083/jcb.201301081 PMID: 24019537
55. Galdiero MR, Garlanda C, Jaillon S, Marone G, Mantovani A. Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol. 2013; 228(7):1404-12. doi:10.1002/jcp.24260 PMID: 23065796
56. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, et al. Macrophage polarization in tumour progression. Semin Cancer Biol. 2008; 18:349-55. doi:10.1016/j.semcancer.2008.03.004 PMID: 18467122
57. Kurahara H, Shinchi H, Mataki Y, Maemura K, Noma H, Kubo F, et al. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res. 2011; 167:e211-9. doi:10.1016/j.jss.2009.05.026 PMID: 19765725
58. Laoui D, Van Overmeire E, Di Conza G, Aldeni C, Keirsse J, Morias Y, et al. Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. Cancer Res. 2013;Epub Nov 12.
59. Liu CY, Xu JY, Shi XY, Huang W, Ruan TY, Xie P, et al. M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway. Lab Invest. 2013; 93(7):844-54. doi:10.1038/labinvest.2013.69 PMID: 23752129
60. Bonde AK, Tsischler V, Kumar S, Soltermann A, Schwendener RA. Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors. BMC Cancer. 2012; 12:35. doi:10.1186/1471-2407-12-35 PMID: 22273460
61. Shabo I, Olsson H, Sun XE, Svanvik J. Expression of the macrophage antigen CD163 in rectal cancer cells is associated with early local recurrence and reduced survival time. Int J Cancer. 2009; 125:1826-31. doi:10.1002/ijc.24506 PMID: 19582880
62. Shabo I, Stal O, Olsson H, Dore S, Svanvik J. Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival. Int J Cancer. 2008; 123(4):780-6. doi:10.1002/ijc.23527 PMID: 18506688
63. Shabo I, Svanvik J. Expression of macrophage antigens by tumor cells. Adv Exp Med Biol. 2011; 714:141-50. doi:10.1007/978-94-007-0782-5-7 PMID: 21506012
64. Pawelek JM. Tumour cell hybridization and metastasis revisited. Melanoma Res. 2000; 10:507-14. PMID: 11198471
65. Pawelek JM. Tumour-cell fusion as a source of myeloid traits in cancer. Lancet Oncol. 2005; 6:988-93. PMID: 16321767
66. Pawelek JM, Chakraborty AK. Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis. Nat Rev Cancer. 2008; 8:377-86. doi:10.1038/nrc2371 PMID: 18385683
67. Goldenberg DM, Rooney RJ, Loo M, Liu DP, Chang C-H. In-Vivo fusion of human cancer and hamster stromal cells permanently transduces and transcribes human DNA. PLoS One. 2014; 9(9):e107927. doi:10.1371/journal.pone.0107927 PMID: 25259521
68. Silk AD, Gast CE, Davies PS, Fakhari FD, Vanderbeek GE, Mori M, et al. Fusion between hematopoietic and epithelial cells in adult human intestine. PLoS One. 2013; 8:e55572. doi:10.1371/journal.pone.0055572 PMID: 23383228
69. Meyer-Siegler KL, Vera PL, Iczkowski KA, Bifulco C, Lee A, Gregersen PK, et al. Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence. Genes Immun. 2007; 8:646-52. PMID: 17728788
70. Kindt N, Lechien J, Decaestecker C, Rodriguez A, Chantrain G, Remmelink M, et al. Expression of macrophage migration-inhibitory factor is correlated with progression in oral cavity carcinomas. Anticancer Res. 2012; 32(10):4499-505. PMID: 23060578
71. Zhang L, Ye SB, Ma G, Tang XF, Chen SP, He J, et al. Th expressions of MIF and CXCR4 protein in tumor microenvironment are advrse prognostic factors in patients with esophageal squamous cell carcinoma. J Transl Med. 2013; 11 (Mar 8):60. doi:10.1186/1479-5876-11-60 PMID: 23497377
72. Schulz R, Marchenko ND, Holembowski L, Fingerle-Rowson G, Pesic M, Zender L, et al. Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression. J Exp Med. 2012; 209(2):275-89. doi:10.1084/jem.20111117 PMID: 22271573
73. Wilson JM, Coletta PL, Cuthbert RJ, Scott N, MacLennan K, Hawcroft G, et al. Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology. 2005; 129:1485-503. PMID: 16285950
74. Wang D, Luo L, Chen W, Chen LZ, Zeng WT, Li W, et al. Significance of the vascular endothelial growth factor and the macrophage migration inhibitory factor in the progression of hepatocellular carcinoma. Oncol Rep. 2014; 31(3):1199-204. doi:10.3892/or.2013.2946 PMID: 24366206
75. Schulz R, Moll UM. Targeting the heat shock protein 90: a rational way to inhibit macrophage migration inhibitory factor function in cancer. Curr Opin Oncol. 2014; 26(1):108-13. doi:10.1097/CCO.0000000000000036 PMID: 24225413
76. Girard E, Strathdee C, Trueblood E, Queva C. Macrophage migration inhibitory factor produced by the tumour stroma but not by tumour cells regulates angiogenesis in the B16-F10 melanoma model. Br J Cancer. 2012; 107(9):1498-505. doi:10.1038/bjc.2012.392 PMID: 22955855
77. Verschuren L, Kooistra T, Bernhagen J, Voshol PJ, Ouwens DM, van Erk M, et al. MIF deficiency reduces chronic inflammation in white adipose tissue and impairs the development of insulin resistance, glucose intolerance, and associated atherosclerotic disease. Circ Res. 2009; 105:99-107. doi:10.1161/CIRCRESAHA.109.199166 PMID: 19478200
78. Yaddanapudi K, Putty K, Rendon BE, Lamont GJ, Faughn JD, Satoskar A, et al. Control of tumorassociated macrophage alternative activation by macrophage migration inhibitory factor. J Immunol. 2013; 190(6):2984-93. doi:10.4049/jimmunol.1201650 PMID: 23390297
79. Liu C-Y, Xu J-Y, Shi X-Y, Huang W, Ruan T-Y, Xie P, et al. M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pnacratic cancer cells, partially through TLR4-IL-10 signaling pathway. Lab Invest. 2013; 93:844-54. doi:10.1038/labinvest.2013.69 PMID: 23752129
80. Funamizu N, Hu C, Lacy C, Schetter A, Zhang G, He P, et al. Macrophage migration inhbitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma. Int J Cancer. 2012;Epub Jul 23.
81. Yoshikawa K, Mitsunaga S, Kinoshita T, Konishi M, Takahashi S, Gotohda N, et al. Impact of tumorassociated macrophages on invasive ductal carcinoma of the pancreas head. Cancer Sci. 2012; 103 (11):2012-20. doi:10.1111/j.1349-7006.2012.02411.x PMID: 22931216
82. Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013; 73(31128-41.).
83. Koong AC, Denko NC, Hudson KM, Schindler C, Swiersz L, Koch C, et al. Candidate genes for the hypoxic tumor phenotype. Cancer Res. 2000; 60:883-7. PMID: 10706099
84. Baugh J, Gantier M, Li L, Byrne A, BUckley A, Donnelly SC. Dual regulation of macrophage migration inhibitory factor (MIF) expression in hypoxa by CREB and HIF-1. Biochem Biophys Res Commun. 2006; 347:895-903. PMID: 16854377
85. Cui Y, Zhang D, Jia Q, Li T, Zhang W, Han J. Proteomic and tissue array profiling identifies elevated hypoxia-regulated proteins in pancreatic ductal adenocarcinoma. Cancer Invest. 2009; 27:747-55. doi:10.1080/07357900802672746 PMID: 19488907
86. Winner M, Koong AC, Rendon BE, Zundel W, Mitchell RA. Amplification of tumor hypoxic responses by macrophage migration inhibitory factor-dependent hypoxia-inducible factor stabilization. Cancer Res. 2007; 67:186-93. PMID: 17210698
87. Kyriakis JM. Thinking outside the box about Ras. J Biol Chem. 2009; 284:10993-4. doi:10.1074/jbc.R800085200 PMID: 19091742
88. Denz A, Pilarsky C, Muth D, Ruckert F, Saeger HD, Grutzmann R. Inhibition of MIF leads to cell cycle arrest and apoptosis in pancreatic cancer cells. J Surg Res. 2010; 160:29-34. doi:10.1016/j.jss.2009.03.048 PMID: 19726058
89. Long J, Luo GH, Liu C, Cui X, Satoh K, Xiao Z, et al. Development of a unique mouse model for pancreatic cancer lymphatic metastasis. Int J Oncol. 2012; 41(5):1662-8. doi:10.3892/ijo.2012.1613 PMID: 22941445
90. Jung H, Seong HA, Ha H. Direct interaction between NM23-H1 and macrophage migration inhibitory factor (MIF) is critical for alleviation of MIF-mediated suppression of p53 activity. J Biol Chem. 2008; 283:32669-79. doi:10.1074/jbc.M806225200 PMID: 18815136
91. Kamphues C, Al-Abadi H, Durr A, Al-Abadi N, Schricke D, Bova R, et al. DNA index as a strong prognostic factor in patients with adenocarcinoma of the pancreatic head: results of a 5-year prospective study. Pancreas. 2013; 42(5):807-12. doi:10.1097/MPA.0b013e3182773eb6 PMID: 23271398
92. Eskelinen M, Lipponen P, Marin S, Haapasalo H, Makinen K, Puittinen J, et al. DNA ploidy, S-phase fraction, and G2 fraction as prognostic determinants in human pancreatic cancer. Scand J Gastroenterol. 1992; 27(1):39-43. PMID: 1736340
93. Eskelinen M, Lipponen P, Collan Y, Marin S, Alhava E, Nordling S. Relationship between DNA ploidy and survival in patients with exocrine pancreatic cancer. Pancreas. 1991; 6:90-5. PMID: 1994384
94. Tsavaris N, Kavantzas N, Tsigritis K, Xynos ID, Papadoniou N, Lazaris A, et al. Evaluation of DNA ploidy in relation with established prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis. BMC Cancer. 2009; 9:264. doi:10.1186/1471-2407-9-264 PMID: 19646258
95. Xynos ID, Kavantzas N, Tsaousi S, Zacharakis M, Agrogiannis G, Kosmas C, et al. Factors influencing survival in Stage IV colorectal cancer: the influence of DNA ploidy. ISRN Gastroenterol. 2013; 2013:490578. doi:10.1155/2013/490578 PMID: 23840958
96. Mijaljica D, Devenish RJ. Nucleophagy at a glance. J Cell Sci. 2013; 126:4325-30. doi:10.1242/jcs.133090 PMID: 24013549
97. Fenech M, Kirsch-Volders M, Natarajan AT, Surralles J, Crott JW, Parry J, et al. Molecular mechanisms of micronucleus, nucleoplasmic bridge and nuclear bud formation in mammalian and human cells. Mutagenesis. 2011; 26:125-32. doi:10.1093/mutage/geq052 PMID: 21164193
98. Rello-Varona S, Lissa D, Shen S, Niso-Santano M, Senovilla L, Marino G, et al. Autophagic removal of micronuclei. Cell Cycle. 2012; 11:170-7. doi:10.4161/cc.11.1.18564 PMID: 22185757
99. Park YE, Hayashi YK, Bonne G, Arimura T, Noguchi S, Nonaka I, et al. Autophagic degradation of nuclear components in mammalian cells. Autophagy. 2009; 5:795-804. PMID: 19550147
100. Pathania AS, Wani ZA, Guru SK, Kumar S, Bhushan S, Korkaya H, et al. The anti-angiogenic and cytotoxic effects of the boswellic acid analog BA145 are potentiated by autphagy inhibitors. Mol Cancer. 2015; 14:6. PMID: 25608686
101. Celton-Morizur S, Desdouets C. Polyploidization of liver cells. Adv Exp Med Biol. 2010; 676:123-35. PMID: 20687473
102. Gandarillas A, Freije A. Cycling up the epidermis: reconciling 100 years of debate. Exp Dermatol. 2014; 23(2):87-91. doi:10.1111/exd.12287 PMID: 24261570
103. Losick VP, Fox DT, Spradling AC. Polyploidization and cell fusion contribute to wound healing in the adult Drosophila epithelium. Curr Biol. 2013; 23(22):2224-32. doi:10.1016/j.cub.2013.09.029 PMID: 24184101
104. Erenpreisa J, Cragg MS. Three steps to the immortality of cancer cells: senescence, polyploidy and self-renewal. Cancer Cell Int. 2013; 13:92. doi:10.1186/1475-2867-13-92 PMID: 24025698
105. Erenpreisa J, Huna A, Salmina K, Jackson TR, Cragg MS. Macroautophagy-aided elimination of chromatin: sort of waste, sorting of fate? Autophagy. 2012; 8:1877-91. PMID: 22935563
106. Erenpreisa J, Salmina K, Huna A, Kosmacek EA, Cragg MS, Ianzini F, et al. Polyploid tumour cells elicit paradiploid progeny through depolyploidizing divisions and regulated autophagic degradation. Cell Biol Int. 2011; 35(7):687-95. doi:10.1042/CBI20100762 PMID: 21250945
107. Schwarz-Finsterle J, Scherthan H, Huna A, Gonzalez P, Mueller P, Schmitt E, et al. Volume increase and spatial shifts of chromosome territories in nuclei of radiation-inducd polyploidizing tumour cells. Mutat Res. 2013; 756:56-65. doi:10.1016/j.mrgentox.2013.05.004 PMID: 23685102